JUN 17, 2019 7:22 AM PDT

Drug Delays Type 1 Diabetes in High Risk Individuals

WRITTEN BY: Nouran Amin

An immunotherapeutic, involving anti-CD3 monoclonal antibody (teplizumab), was seen to slow down the progression to clinical type 1 diabetes in high risk individuals. Findings from the National Institutes of Health-funded research show that clinical type 1 diabetes can be delayed by two or more years for individuals at high risk.

"The difference in outcomes was striking. This discovery is the first evidence we've seen that clinical type 1 diabetes can be delayed with early preventive treatment," said Lisa Spain, Ph.D., Project Scientist from the NIH's National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), sponsor of TrialNet. "The results have important implications for people, particularly youth, who have relatives with the disease, as these individuals may be at high risk and benefit from early screening and treatment."

These results were published online in The New England Journal of Medicine and presented at the American Diabetes Association Scientific Sessions in San Francisco.

"Previous clinical research funded by the NIH found that teplizumab effectively slows the loss of beta cells in people with recent onset clinical type 1 diabetes, but the drug had never been tested in people who did not have clinical disease," said Kevan C. Herold, M.D., of Yale University, the study's lead author. "We wanted to see whether early intervention would have a benefit for people who are at high risk but do not yet have symptoms of type 1 diabetes."

Type 1 diabetes is a result of the immune system attacking its own insulin-producing cells. Insulin is critical for converting glucose into energy. However, with Teplizumab, it works by targeting the cells that recognize the insulin producing cells as ‘foreign’—lessening the destruction.

Learn more about Type 1 Diabetes:

"While the results are encouraging, more research needs to be done to address the trial's limitations, as well as to fully understand the mechanisms of action, long-term efficacy and safety of the treatment," said Dr. Spain.

"This trial illustrates how decades of research on the biology of type 1 diabetes can lead to promising treatments that have a real impact on people's lives. We're very excited to see the next steps in this research," said Dr. Griffin P. Rodgers, NIDDK Director. "The dedicated researchers, volunteers and families participating in this program make discoveries like this possible."

Source: National Institutes of Health

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
OCT 05, 2020
Drug Discovery & Development
Fecal Transplants Could Restore Cognitive Function in the Elderly
OCT 05, 2020
Fecal Transplants Could Restore Cognitive Function in the Elderly
An international team of researchers has found that fecal transplants could one day be used to restore cognitive functio ...
OCT 23, 2020
Drug Discovery & Development
FDA Gives Full Approval to Remdesivir to Treat COVID-19
OCT 23, 2020
FDA Gives Full Approval to Remdesivir to Treat COVID-19
The US Food and Drug Administration (FDA) has approved antiviral drug Remdesivir, sold under the name ‘Velkury&rsq ...
OCT 01, 2020
Drug Discovery & Development
Antidepressants Treats Lazy Eye
OCT 01, 2020
Antidepressants Treats Lazy Eye
A study published in Current Biology revealed how a therapeutic used as an antidepressant and for managing pain could tr ...
OCT 06, 2020
Drug Discovery & Development
Drug For A Severe E. Coli Infection
OCT 06, 2020
Drug For A Severe E. Coli Infection
Escherichia coli, known as E. coli, is a popular bacterium associated with food poisoning and depending on the strain ca ...
NOV 15, 2020
Drug Discovery & Development
Drug Stimulates Female Fertility
NOV 15, 2020
Drug Stimulates Female Fertility
A recent drug, MVT-602, was found to stimulate fertility by acting on the natural 'kisspeptin' hormone system in ...
NOV 25, 2020
Drug Discovery & Development
Improving Drug Dissolution
NOV 25, 2020
Improving Drug Dissolution
When you take your medicine, it travels through the bloodstream and releases its effects. When the drug dissolves too fa ...
Loading Comments...